首页> 美国卫生研究院文献>Journal of Biomedical Research >Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
【2h】

Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA

机译:用于免疫印迹和夹心ELISA的抗GP73单克隆抗体的产生和表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellular carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent assay (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recombinant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blotting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).
机译:近来,已经发现肝细胞癌(HCC)患者的血清高尔基蛋白73(GP73)水平升高,并且GP73已被提议作为HCC的新标志物。但是,由于基于抗GP73抗体的酶联免疫吸附测定(ELISA)的特异性,患者中的GP73水平仍存在争议。因此,非常需要具有高特异性的抗GP73抗体。在本研究中,通过杂交瘤筛选,我们使用原核表达产生的重组GP73蛋白生成了命名为6A2的抗GP73单克隆抗体(mAb)。通过蛋白质印迹,免疫组织化学和免疫沉淀评估6A2的特异性。结果表明6A2以天然和变性形式识别GP73。此外,我们已经按照标准程序,使用在新西兰白兔中产生的6A2和GP73多克隆抗体,开发了一种夹心ELISA,并使用该测定法测量了患者的血清GP73水平。我们的结果表明,HCC患者的血清GP73水平显着高于健康对照组(P = 0.0036)。此外,与健康对照组相比,乳腺癌患者中的GP73血清水平首次被发现升高(P = 0.0172)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号